Search Results - "Pond, G R"

C-statistic: A brief explanation of its construction, interpretation and limitations by Caetano, S.J., Sonpavde, G., Pond, G.R.

“…A brief explanation, interpretation and limitations of clinical statistics is presented. Model validation has traditionally been performed by splitting the…”
Get full text

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy by Balitsky, Amaris, Pond, G R, Davies, G A, Fraser, G, Kouroukis, T, Levine, M, Meyer, R M, Foley, R

“…Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious…”
Get full text

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials by Templeton, A.J., Vera-Badillo, F.E., Wang, L., Attalla, M., De Gouveia, P., Leibowitz-Amit, R., Knox, J.J., Moore, M., Sridhar, S.S., Joshua, A.M., Pond, G.R., Amir, E., Tannock, I.F.

“…Multiple factors can influence outcomes of patients receiving identical interventions in clinical trials and in routine practice. Here, we compare outcomes of…”
Get full text

Cognitive function and fatigue after diagnosis of colorectal cancer by Vardy, J., Dhillon, H.M., Pond, G.R., Rourke, S.B., Xu, W., Dodd, A., Renton, C., Park, A., Bekele, T., Ringash, J., Zhang, H., Burkes, R., Clarke, S.J., Tannock, I.F.

“…Cognitive impairment and fatigue have been associated with cancer and its treatment. We present baseline data from a large longitudinal study that evaluates…”
Get full text

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas by DURAN, I, KORTMANSKY, J, BIRLE, D, POND, G. R, ARBOINE, D, DANCEY, J, AVIEL-RONEN, S, TSAO, M.-S, HEDLEY, D, SIU, L. L, SINGH, D, HIRTE, H, KOCHA, W, GOSS, G, LE, L, OZA, A, NICKLEE, T, HO, J

“…Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to…”
Get full text

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy by Bane, A.L., Whelan, T.J., Pond, G.R., Parpia, S., Gohla, G., Fyles, A.W., Pignol, J.-P., Pritchard, K.I., Chambers, S., Levine, M.N.

“…To determine whether tumor grade, molecular subtype and hypoxia predict response to hypofractionated versus standard radiotherapy (RT) following…”
Get full text

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy by VARDY, J, CHIEW, K. S, GALICA, J, POND, G. R, TANNOCK, I. F

“…The role of dexamethasone to reduce delayed emesis following highly emetogenic chemotherapy is proven, but there is less evidence of benefit after…”
Get full text

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab by Blanchette, P. S., Desautels, D. N., Pond, G. R., Bartlett, J. M. S., Nofech-Mozes, S., Yaffe, M. J., Pritchard, K. I.

“…Purpose We have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to…”
Get full text

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study by Jerzak, K. J., Cockburn, J. G., Dhesy-Thind, S. K., Pond, G. R., Pritchard, K. I., Nofech-Mozes, S., Sun, P., Narod, S. A., Bane, A.

“…Purpose Preliminary data suggest that high expression of the TRβ1 tumor suppressor is associated with longer survival among women with early breast cancer. We…”
Get full text

Statistical issues in the use of dynamic allocation methods for balancing baseline covariates by Pond, G R

“…Background: The procedure for allocating patients to a treatment arm in comparative clinical trials is frequently chosen with only minor deliberation. This…”
Get full text

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa by Berthold, D.R., Pond, G.R., de Wit, R., Eisenberger, M., Tannock, I.F.

“…The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic…”
Get full text

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus by Duran, I., Siu, L.L., Oza, A.M., Chung, T.-B., Sturgeon, J., Townsley, C.A., Pond, G.R., Seymour, L., Niroumand, M.

“…The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus,…”
Get full text

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer by TOWNSLEY, C. A, MAJOR, P, MOORE, M. J, OZA, A. M, SIU, L. L, DANCEY, J, CHEN, E, POND, G. R, NICKLEE, T, HO, J, HEDLEY, D, TSAO, M

“…Erlotinib (Tarceva, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its…”
Get full text

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials by Tang, P. A., Pond, G. R., Chen, E. X.

“…Background: Our objective was to determine the variability in assessment between investigators (INV) and independent review committees (IRC) for response rate…”
Get full text

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study by Hotte, S.J., Oza, A., Winquist, E.W., Moore, M., Chen, E.X., Brown, S., Pond, G.R., Dancey, J.E., Hirte, H.W.

“…Background: 7-Hydroxystaurosporine (UCN-01) inhibits serine–threonine kinases including the Ca2+ and phospholipid-dependent protein kinase C (PKC), CDKs 2, 4,…”
Get full text

Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods by Seruga, B., Pond, G.R., Hertz, P.C., Amir, E., Ocana, A., Tannock, I.F.

“…Reporting of relative risk reduction as the measure of treatment effect in randomized clinical trials (RCTs) may be difficult to understand. Here, we compare…”
Get full text

Direct medical costs attributable to osteoporotic fractures by GABRIEL, S. E, TOSTESON, A. N. A, LEIBSON, C. L, CROWSON, C. S, POND, G. R, HAMMOND, C. S, MELTON, L. J

“…Osteoporotic fractures are a major cause of morbidity in the elderly, the most rapidly growing segment of our population. We characterized the incremental…”
Get full text

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study by Fernandes, R., Mazzarello, S., Joy, A. A., Pond, G. R., Hilton, J., Ibrahim, M. F. K., Canil, C., Ong, M., Stober, C., Vandermeer, L., Hutton, B., da Costa, M., Damaraju, S., Clemons, Mark

“…Background Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 2–3 days after taxane-based chemotherapy and lasting up to…”
Get full text

Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation by HASEGAWA, W, POND, G. R, RIFKIND, J. T, MESSNER, H. A, LAU, A, DALY, A. S, KISS, T. L, KOTCHETKOVA, N, GALAL, A, LIPTON, J. H

“…The purpose of this study was to evaluate the estimated incidence of secondary malignancies post-allogeneic bone marrow transplantation (BMT) in a cohort of…”
Get full text

Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006 by Ng, R., Pond, G.R., Tang, P.A., MacIntosh, P.W., Siu, L.L., Chen, E.X.

“…Although disease-free survival (DFS) is accepted as a valid end point in adjuvant breast cancer trials, improvement in 2-year DFS has never been formally…”
Get full text